Company: EUDAW
Filing Date: 2025-06-24
Form Type: 424B5
Source: 0001641172-25-016185
Chunk: 21

Company: EUDA Health Holdings Ltd
Filing Date: 2025-06-24
Form: 424B5
Chunk 21
---
 pay the Agent a commission equal to (a) 3% of the gross proceeds of Shares sold directly into the market pursuant to each Sales Notice or (b) 7% if sold through institutional or broker-to-broker “block” transactions. Since there is no minimum offering amount required as a condition to close this offering, the actual total public offering size, commissions, and proceeds to us, if any, are not determinable at this time. In connection with the sale of the ordinary shares on our behalf, Chardan will be deemed an “underwriter” within the meaning of the Securities Act, and the compensation of the Agent will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the Agent with respect to certain civil liabilities, including liabilities under the Securities Act. We have also agreed to reimburse the Agent for certain expenses incurred in connection with the offering of our ordinary shares pursuant to Sales Agreement, which is not to exceed the higher of (a) $75,000 for pre-Commitment Period Diligence and $15,000 for follow on diligence exercises; and (b) an amount approved by the Company and incurred by Chardan in the course of its efforts in support of the transactions referenced herein. We estimate that our total expenses for the offering, excluding compensation payable to the Agent under the terms of the Sales Agreement, will be approximately $66,000.00.

The offering of our ordinary shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all of our ordinary shares provided for in this prospectus supplement, (ii) the thirty (30) days after written notice of termination by the Company, or (iii) immediately under certain conditions by the Agent as defined by the Sales Agreement. This summary of the material provisions of the Sales Agreement does not purport to be a complete statement of its terms and conditions.

Our Agent and its affiliates may in the future provide various investment banking, commercial banking, and other financial services for us and our affiliates, for which services they may in the future receive customary fees.

This prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by our Agent who may distribute this prospectus supplement and the accompanying prospectus electronically.

To the extent required by Regulation M, the Agent will not engage in any market making activities involving our ordinary shares while the offering is ongoing under this prospectus supplement.

| S-14 |

<div align='center'>LEGAL MATTERS</div